ELVN - NASDAQ
Enliven Therapeutics, Inc.
$37.48
+4.0%Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
At a Glance
Live SnapshotEnliven Therapeutics, Inc. Management Team
Mr. Benjamin Hohl
Chief Financial Officer & Head of Corporate Development
Compensation
$488,500
Dr. Galya D. Blachman Esq., Ph.D.
Chief Legal Officer & Head of Business Development
Dr. Helen Louise Collins M.D.
Chief Medical Officer
Compensation
$746,400
Mr. Anish Patel Pharm.D.
Co-Founder & Chief Operating Officer
Dr. Joseph P. Lyssikatos Ph.D.
Co-Founder & Chief Scientific Officer
Compensation
$709,400
Mr. Samuel S. Kintz M.B.A.
Co-Founder, Chief Executive Officer, Secretary & Director
Compensation
$973,800
Enliven Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $7.70M worth of ELVN shares, with no buying activity reported.
3 Months
0
0.00
98.6K
3.19M
-3.2M
-$3.19M
3-6 Months
0
0.00
122.2K
3.18M
-3.2M
-$3.18M
6-9 Months
0
0.00
65.5K
1.33M
-1.3M
-$1.33M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Collins Helen Louise
Officer: Chief Medical Officer
$4.07M
Patel Anish
Officer: Chief Operating Officer
$1.69M
Lyssikatos Joseph P
Officer: Chief Scientific Officer
$1.07M
Kintz Samuel
Director, Officer: President And Ceo
$539K
Hohl Benjamin
Officer: Chief Financial Officer
$304K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $7.70M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
ELVN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 09, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 18, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 23, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | May 18, 2021 | June 29, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.